(VIANEWS) – SPAREBANKEN SØR (SOR.OL), BOURSE DIRECT (BSD.PA), TUBIZE-FIN (TUB.BR) are the highest payout ratio stocks on this list.
We have gathered information concerning stocks with the highest payout ratio up until now. The payout ratio in itself isn’t a guarantee of good investment but it’s an indicator of whether dividends are being paid and how the company chooses to issue them.
When investigating a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.
1. SPAREBANKEN SØR (SOR.OL)
67.23% Payout Ratio
Sparebanken Sør operates as an independent financial institution in Norway. It operates through two segments, Retail Market and Corporate Market. The company is involved in banking, securities trading, and real estate brokerage activities in Agder, Rogaland, Vestfold, and Telemark counties. It also provides leasing, mortgage, and property management services; and sells general insurance, occupational pension, and group life insurance products. The company was founded in 1824 and is headquartered in Kristiansand, Norway. Sparebanken Sør operates as a subsidiary of Sparebankstiftelsen Sparebanken Sør.
Earnings Per Share
As for profitability, SPAREBANKEN SØR has a trailing twelve months EPS of kr12.04.
PE Ratio
SPAREBANKEN SØR has a trailing twelve months price to earnings ratio of 10.59. Meaning, the purchaser of the share is investing kr10.59 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.36%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 27%, now sitting on 2.76B for the twelve trailing months.
Moving Average
SPAREBANKEN SØR’s value is under its 50-day moving average of kr128.99 and below its 200-day moving average of kr129.07.
More news about SPAREBANKEN SØR.
2. BOURSE DIRECT (BSD.PA)
50.37% Payout Ratio
Bourse Direct SA provides Internet stock brokerage services in France. It offers a platform of services, tools, and financial products, including French and foreign equities, derivatives, trackers, warrants, certificates, turbos, mutual funds, UCITS, and CFDs, as well as tax exemption, retirement, real estate, and life insurance products through the boursedirect.fr, capitol.fr, tradebox.fr, abssysteme.fr, wargny.com, and mesactions.com sites. The company was founded in 1996 and is headquartered in Paris, France. Bourse Direct SA is a subsidiary of E-VIEL SA.
Earnings Per Share
As for profitability, BOURSE DIRECT has a trailing twelve months EPS of €0.13.
PE Ratio
BOURSE DIRECT has a trailing twelve months price to earnings ratio of 34.23. Meaning, the purchaser of the share is investing €34.23 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.29%.
More news about BOURSE DIRECT.
3. TUBIZE-FIN (TUB.BR)
39.2% Payout Ratio
Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Evenity, an injection for osteoporosis; and Bimzelx to treat moderate to severe plaque psoriasis. The company's products in pipeline include Staccato to treat stereotypical prolonged seizures; Bepranemab for the treatment of Alzheimer's disease; UCB0599 for Parkinson's disease; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize SA is based in Brussels, Belgium.
Earnings Per Share
As for profitability, TUBIZE-FIN has a trailing twelve months EPS of €1.84.
PE Ratio
TUBIZE-FIN has a trailing twelve months price to earnings ratio of 40.27. Meaning, the purchaser of the share is investing €40.27 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.88%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on May 3, 2023, the estimated forward annual dividend rate is 0.86 and the estimated forward annual dividend yield is 1.09%.
Moving Average
TUBIZE-FIN’s value is below its 50-day moving average of €76.58 and above its 200-day moving average of €72.31.
Yearly Top and Bottom Value
TUBIZE-FIN’s stock is valued at €74.10 at 07:10 EST, way below its 52-week high of €94.10 and way higher than its 52-week low of €65.40.
More news about TUBIZE-FIN.
4. BOIRON (BOI.PA)
32.87% Payout Ratio
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary, proprietary, branded homeopathic medicines. Its branded homeopathic medicines include Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; and Sédatif PC to treat anxiety and emotional, and minor sleep disorders. The company's homeopathic medicines also comprise Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; and Homéovox for vocal disorders. In addition, it provides dietary supplement; Dermoplasmine stick, baume, and mousse to treat dry lips and skin; Mag' Nuit, a formula to fall asleep; Arnitrosium for joint pain; Castor Equi Boiron ointment for treatment of cracked skin; and Storinyl, a syrup to treat colds. Further, it offers herbal medicines, such as Canephron to increase the amount of urine and to improve urinary elimination; moisturizing baby milk; and medical devices, including a range of COVID self-tests and rapid antigenic tests. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.
Earnings Per Share
As for profitability, BOIRON has a trailing twelve months EPS of €2.97.
PE Ratio
BOIRON has a trailing twelve months price to earnings ratio of 13.55. Meaning, the purchaser of the share is investing €13.55 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.13%.
More news about BOIRON.
